NCT06694935

A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

A Phase 1b Study of QX1206 in Type 2 Diabetes Mellitus (T2DM) Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (estimated)
• Sponsor: 1Globe Health Institute · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.

Conditions

• Type 2 Diabetes Mellitus (T2DM)
• Non-Alcoholic Fatty Liver Disease (NAFLD)

Interventions

Type	Name	Description
DRUG	QX1206	QX1206 will be administered orally before bedtime

Timeline

• Start date: 2025-01-06
• Primary completion: 2025-07-01
• Completion: 2025-12-01
• First posted: 2024-11-19
• Last updated: 2025-01-13

Locations

1 site across 1 country: Canada